These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184 [TBL] [Abstract][Full Text] [Related]
47. Attention to Infliximab adverse events: chimeric monoclonal antibodies can induce anti chimeric antibodies that may result in Kounis hypersensitivity associated acute coronary syndrome. Kounis NG; Kounis GN; Soufras GD; Tsigkas G; Hahalis G Eur Rev Med Pharmacol Sci; 2014; 18(24):3735-6. PubMed ID: 25555859 [No Abstract] [Full Text] [Related]
48. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease]. Meier J; Sturm A Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829 [No Abstract] [Full Text] [Related]
50. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels. Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455 [TBL] [Abstract][Full Text] [Related]
51. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. van Schaik T; Maljaars JP; Roopram RK; Verwey MH; Ipenburg N; Hardwick JC; Veenendaal RA; van der Meulen-de Jong AE Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167 [TBL] [Abstract][Full Text] [Related]
52. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?]. Moum B Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118 [No Abstract] [Full Text] [Related]
54. Immunogenicity of infliximab in Crohn's disease. Hanauer SB N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378 [No Abstract] [Full Text] [Related]
55. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. Li X; Lu C; Yang Y; Yu C; Rao Y Biomed Pharmacother; 2020 Sep; 129():110486. PubMed ID: 32768972 [TBL] [Abstract][Full Text] [Related]
56. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Quetglas EG; Armuzzi A; Wigge S; Fiorino G; Barnscheid L; Froelich M; Danese S Eur J Clin Pharmacol; 2015 Jul; 71(7):773-99. PubMed ID: 26008212 [TBL] [Abstract][Full Text] [Related]
57. Long-Term Clinical Outcomes After Switching from Remicade Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429 [TBL] [Abstract][Full Text] [Related]
58. Does everyone with inflammatory bowel disease need to be treated with combination therapy? Bernstein CN Curr Opin Gastroenterol; 2016 Jul; 32(4):287-93. PubMed ID: 27115220 [TBL] [Abstract][Full Text] [Related]
59. Earlier need of infliximab intensification in ulcerative colitis than in Crohn's disease. Magro F; Rodrigues-Pinto E; Lopes S; Macedo G J Crohns Colitis; 2014 Oct; 8(10):1331-2. PubMed ID: 24690137 [No Abstract] [Full Text] [Related]
60. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA Scand J Gastroenterol; 2011 Mar; 46(3):310-8. PubMed ID: 21087119 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]